Current Diabetes Reviews

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back Subscribe
Review Article

Review: Fructose, the Sweet Culprit behind Nonalcoholic Fatty Liver Disease and Type 2 Diabetes

Author(s): Abdullah Y. Otayforcid of author, Gaurav Agarwal*orcid of author, Muzaynah Al Khairat, Elham Ahmed Khormi, Hamzah Hassan Alnemi, Ahmad Ali Alhazmi, Khalid Abutawil and Shilpi Agarwalauthors OrcID

Volume 22, Issue 2, 2026

Published on: 04 February, 2025

Article ID: e15733998336827

Pages: 11

DOI: 10.2174/0115733998336827250114071627

open_access

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

The composition of the diet has altered over the past few decades, with a significant increase in the consumption of dietary sugars, particularly fructose, which has risen more than tenfold. This elevated consumption of fructose and sugars is considered to be one of the major risk aspects for the emergence of obesity and other metabolic disorders. In this review, we discuss the correlation between insulin resistance and NAFLD (nonalcoholic fatty liver disease) due to dietary fructose intake. Type 2 Diabetes Mellitus (T2DM) is spreading quickly over the world and has epidemic proportions. The risk of both hepatic and metabolic abnormalities is increased by their connection, founded on shared metabolic risk factors such as obesity, (IR) Insulin Resistance, and an unhealthy standard of living. This review highlights the prevalence of coexisting T2DM (Type 2 diabetes) and NAFLD (Non-alcoholic Fatty Liver Disease) in the community. In summary, the key pathophysiological pathways and risk stratification algorithms for the onset of nonalcoholic fatty liver disease and type 2 diabetes have been covered.

Keywords: Insulin resistance, nonalcoholic fatty liver disease, dietary fructose, type 2 diabetes mellitus, dietary sugars, non-alcoholic steatohepatitis, fructose.

[1]
Younossi ZM. Non-alcoholic fatty liver disease: A global public health perspective. J Hepatol 2019; 70(3): 531-44.
[http://dx.doi.org/10.1016/j.jhep.2018.10.033] [PMID: 30414863]
[2]
Qi Y, Fan L, Ran D, et al. Main risk factors of type 2 diabetes mellitus with nonalcoholic fatty liver disease and hepatocellular carcinoma. J Oncol 2021; 2021: 1-10.
[http://dx.doi.org/10.1155/2021/7764817] [PMID: 34691178]
[3]
Lazarus JV, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol 2022; 76(4): 771-80.
[http://dx.doi.org/10.1016/j.jhep.2021.10.025] [PMID: 34895743]
[4]
Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020; 111: 154170.
[http://dx.doi.org/10.1016/j.metabol.2020.154170] [PMID: 32006558]
[5]
Lodge M, Dykes R, Kennedy A. Regulation of fructose metabolism in nonalcoholic fatty liver disease. Biomolecules 2024; 14(7): 845.
[http://dx.doi.org/10.3390/biom14070845] [PMID: 39062559]
[6]
Softic S, Cohen DE, Kahn CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci 2016; 61(5): 1282-93.
[http://dx.doi.org/10.1007/s10620-016-4054-0] [PMID: 26856717]
[7]
Sodhi K, Singh V, et al. Mechanisms of fructose-induced metabolic syndrome and cardiovascular disease. Am J Physiol Endocrinol Metab 2015; 309(5)
[http://dx.doi.org/10.1152/ajpendo.00163.2015]
[8]
Basciano H, Federico L, Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab (Lond) 2005; 2(1): 5.
[http://dx.doi.org/10.1186/1743-7075-2-5] [PMID: 15723702]
[9]
Su Q, Tsai J, Xu E, et al. ER stress links obesity to hepatic insulin resistance. J Lipid Res 2009; 50(8): 1529-40.
[http://dx.doi.org/10.1194/jlr.M800683-JLR200]
[10]
Lambertz J, Weiskirchen S, et al. Gut-liver axis in the progression of NAFLD: Impact of fructose. J Hepatol 2017; 67(6): 1086-96.
[http://dx.doi.org/10.1016/j.jhep.2017.03.012]
[11]
McGarry JD. Dysregulation of fatty acid metabolism in diabetes. Diabetes 1992; 41(8): 962-70.
[http://dx.doi.org/10.2337/diab.41.8.962] [PMID: 1628771]
[12]
Firneisz G. Non-alcoholic fatty liver disease and insulin resistance: From pathophysiology to treatment. World J Gastroenterol 2014; 20(28): 8412-21.
[http://dx.doi.org/10.3748/wjg.v20.i28.8412]
[13]
Wang Y, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol 2015; 16(11): 678-89.
[http://dx.doi.org/10.1038/nrm4074] [PMID: 26490400]
[14]
Berger T, Togawa A, Duncan GS, et al. Lipocalin-2 deficiency and its role in hepatic metabolism and inflammation. Nat Med 2006; 12(4): 444-50.
[http://dx.doi.org/10.1038/nm1345]
[15]
Botezelli JD, Mora RF, Dalia RA, et al. Modulation of insulin signaling by high-fructose diets. Mol Nutr Food Res 2010; 54(4): 419-26.
[http://dx.doi.org/10.1002/mnfr.200900438]
[16]
Alwahsh SM, Xu M, Seyhan HA, Ahmad S, Mihm S, Ramadori G. Liver inflammation and fibrosis induced by a fructose-enriched diet. Eur J Nutr 2014; 53(1): 83-93.
[http://dx.doi.org/10.1007/s00394-013-0585-8] [PMID: 23417688]
[17]
Ferraris RP, Diamond J. Regulation of intestinal sugar transport. Physiol Rev 1997; 77(1): 257-302.
[http://dx.doi.org/10.1152/physrev.1997.77.1.257] [PMID: 9016304]
[18]
Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis in fatty liver. Hepatology 2014; 60(4): 1330-40.
[http://dx.doi.org/10.1002/hep.27049] [PMID: 24316260]
[19]
Janssen U, Haferkamp A, Jonas U. Inflammation-induced by Kupffer cells during fructose metabolism. J Hepatol 2018; 69(2): 390-400.
[http://dx.doi.org/10.1016/j.jhep.2018.07.004]
[20]
Kasper P, Martin A, Lang S, Kütting F, et al. Targeting oxidative stress in NAFLD treatment. Liver Int 2018; 38(1): 25-38.
[http://dx.doi.org/10.1111/liv.13684]
[21]
Weiss R, Bremer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Obes Rev 2008; 9(4): 303-18.
[http://dx.doi.org/10.1111/j.1467-789X.2008.00499.x]
[22]
Ritze Y, Bardos G, Schäffler A, et al. Endotoxemia and liver injury induced by high-fructose feeding. Nutr 2014; 30(4): 409-17.
[http://dx.doi.org/10.1016/j.nut.2014.02.010]
[23]
Kneeman JM, Misdraji J, Corey KE. Liver fibrosis, inflammation, and insulin resistance. J Clin Invest 2016; 126(4): 1133-42.
[http://dx.doi.org/10.1172/JCI79153]
[24]
D'Alessandro, ME.; Oliva, ME.; Ferreira, MR.; Selenscig, D.; Lombardo, YB.; Chicco, A. Sucrose-rich feeding during rat pregnancy-lactation and/or after weaning alters glucose and lipid metabolism in adult offspring. Clin Exper Pharmacol Physiol 2012; 39(7): 623-9.
[http://dx.doi.org/10.1038/s41467-018-03482-w] [PMID: 29386506]
[25]
Hannou SA, Haslam DE, McKeown NM, Herman MA. Fructose metabolism and metabolic disease. J Clin Invest 2018; 128(2): 545-55.
[http://dx.doi.org/10.1172/JCI96702] [PMID: 29388924]
[26]
Roeb E, Steffen HM, Bantel H, et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol 2015; 53(7): 668-723.
[http://dx.doi.org/10.1055/s-0035-1553193] [PMID: 26167698]
[27]
Roeb, E.; Weiskirchen, R. Fructose and non-alcoholic steatohepatitis. Front Pharmacol 2021; 66(8): 12-634344.
[http://dx.doi.org/10.1016/j.jhep.2016.12.025] [PMID: 28214020]
[28]
de Castro UGM, dos Santos RASAS, Silva ME, de Lima WG, Campagnole-Santos MJ, Alzamora AC. Age-dependent effect of high-fructose and high-fat diets on lipid metabolism and lipid accumulation in liver and kidney of rats. Lipids Health Dis 2013; 12(1): 136.
[http://dx.doi.org/10.1186/1476-511X-12-136] [PMID: 24044579]
[29]
Dornas WC, de Lima WG, Pedrosa ML, Silva ME. Health implications of high-fructose intake and current research. Adv Nutr 2015; 6(6): 729-37.
[http://dx.doi.org/10.3945/an.114.008144] [PMID: 26567197]
[30]
Softic S, Stanhope KL, Boucher J, et al. Fructose and hepatic insulin resistance. Crit Rev Clin Lab Sci 2019; 57(5): 308.
[http://dx.doi.org/10.1080/10408363.2019.1711360]
[31]
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73(1): 202-9.
[http://dx.doi.org/10.1016/j.jhep.2020.03.039] [PMID: 32278004]
[32]
Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int 2020; 40(6): 1254-61.
[http://dx.doi.org/10.1111/liv.14478] [PMID: 32301554]
[33]
Eslam M, Sanyal AJ, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158(7): 1999-2014.e1.
[http://dx.doi.org/10.1053/j.gastro.2019.11.312] [PMID: 32044314]
[34]
Atan NAD, Koushki M, Motedayen M, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: A systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench 2017; 10: 1-7.
[PMID: 29511464]
[35]
Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30(5): 1212-8.
[http://dx.doi.org/10.2337/dc06-2247] [PMID: 17277038]
[36]
Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: The Edinburgh type 2 diabetes study. Diabetes Care 2011; 34(5): 1139-44.
[http://dx.doi.org/10.2337/dc10-2229] [PMID: 21478462]
[37]
Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019; 71(4): 793-801.
[http://dx.doi.org/10.1016/j.jhep.2019.06.021] [PMID: 31279902]
[38]
Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis. Diabetes Care 2018; 41(2): 372-82.
[http://dx.doi.org/10.2337/dc17-1902] [PMID: 29358469]
[39]
Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136(5): 1585-92.
[http://dx.doi.org/10.1053/j.gastro.2009.01.050] [PMID: 19208353]
[40]
Gu Z, Bi Y, Yuan F, et al. FTO polymorphisms are associated with metabolic dysfunction-associated fatty liver disease (MAFLD) susceptibility in the older chinese han population. Clin Interv Aging 2020; 15: 1333-41.
[http://dx.doi.org/10.2147/CIA.S254740] [PMID: 32848374]
[41]
Claussnitzer M, Dankel SN, Kim KH, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med 2015; 373(10): 895-907.
[http://dx.doi.org/10.1056/NEJMoa1502214] [PMID: 26287746]
[42]
Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021; 17(8): 484-95.
[http://dx.doi.org/10.1038/s41574-021-00507-z] [PMID: 34131333]
[43]
Smith G, Polidori DC, Yoshino M, Kearney ML, et al. Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on mitochondrial function in liver and skeletal muscle of sedentary older women and men. Diabetes 2016; 65(4): 894-9.
[http://dx.doi.org/10.2337/db15-1132]
[44]
Brunt EM, Wong VWS, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015; 1(1): 15080.
[http://dx.doi.org/10.1038/nrdp.2015.80] [PMID: 27188459]
[45]
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6): 1388-402.
[http://dx.doi.org/10.1016/j.jhep.2015.11.004] [PMID: 27062661]
[46]
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the study of liver diseases. Hepatology 2018; 67(1): 328-57.
[http://dx.doi.org/10.1002/hep.29367] [PMID: 28714183]
[47]
Noureddin M, Jones C, Alkhouri N, et al. Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the united states is cost-effective: A comprehensive cost-utility analysis. Gastroenterology 2020; 159(5): 1985-1987.e4.
[http://dx.doi.org/10.1053/j.gastro.2020.07.050] [PMID: 32763241]
[48]
Long MT, Noureddin M, Lim JK. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review. Gastroenterology 2022; 163(3): 764-774.e1.
[http://dx.doi.org/10.1053/j.gastro.2022.06.023] [PMID: 35842345]
[49]
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018; 67(1): 123-33.
[http://dx.doi.org/10.1002/hep.29466] [PMID: 28802062]
[50]
Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology 2013; 57(6): 2525-31.
[http://dx.doi.org/10.1002/hep.26299] [PMID: 23390127]
[51]
Malik VS, Hu FB. Fructose and cardiometabolic health. J Am Coll Cardiol 2015; 66(14): 1615-24.
[http://dx.doi.org/10.1016/j.jacc.2015.08.025] [PMID: 26429086]
[52]
Bray GA. How bad is fructose?1,2. Am J Clin Nutr 2007; 86(4): 895-6.
[http://dx.doi.org/10.1093/ajcn/86.4.895] [PMID: 17921361]
[53]
Tappy L, Lê KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010; 90(1): 23-46.
[http://dx.doi.org/10.1152/physrev.00019.2009] [PMID: 20086073]
[54]
Stanhope KL, Havel PJ. Fructose consumption: Recent results and their potential implications. Ann N Y Acad Sci 2010; 1190(1): 15-24.
[http://dx.doi.org/10.1111/j.1749-6632.2009.05266.x] [PMID: 20388133]
[55]
Lustig RH. Fructose: Metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010; 110(9): 1307-21.
[http://dx.doi.org/10.1016/j.jada.2010.06.008] [PMID: 20800122]
[56]
Rippe JM, Angelopoulos TJ. Fructose-containing sugars and cardiovascular disease. Adv Nutr 2015; 6(4): 430-9.
[http://dx.doi.org/10.3945/an.114.008177] [PMID: 26178027]
[57]
Malik VS, Popkin BM, Bray GA, Després JP, Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010; 121(11): 1356-64.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.876185] [PMID: 20308626]
[58]
Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Fructose consumption among US adults and children. Medscape J Med 2008; 10(7): 160.
[http://dx.doi.org/10.1002/hep.26152] [PMID: 18769702]
[59]
Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119(5): 1322-34.
[http://dx.doi.org/10.1172/JCI37385] [PMID: 19381015]
[60]
Stanhope KL, Bremer AA, Medici V, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metabv 2011; 96(10): E1596-605.
[http://dx.doi.org/10.1210/jc.2011-1251]
[61]
Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: Systematic review and meta-analysis. BMJ 2013; 346
[http://dx.doi.org/10.1136/bmj.e7492] [PMID: 23321486]
[62]
Bray GA, Popkin BM. Dietary sugar and body weight: Have we reached a crisis in public health? Health Aff (Millwood) 2014; 33(9): 1784-90.
[http://dx.doi.org/10.1377/hlthaff.2013.0719]
[63]
Aeberli I, Gerber PA, Hochuli M, et al. Fructose intake and insulin resistance. J Hepatol 2011; 55(6): 1163-9.
[http://dx.doi.org/10.1016/j.jhep.2011.02.025]
[64]
Sievenpiper JL, de Souza RJ, Mirrahimi A, et al. Effect of fructose on body weight: A systematic review and meta-analysis of controlled feeding trials. Ann Intern Med 2012; 156(4): 291-304.
[http://dx.doi.org/10.7326/0003-4819-156-4-201202210-00007] [PMID: 22351714]
[65]
Taskinen MR, Söderlund S, Bogl LH, et al. Adverse effects of fructose on lipid metabolism. Nutrients 2017; 9(4): 356.
[http://dx.doi.org/10.3390/nu9040356] [PMID: 28368361]
[66]
Johnson RJ, Sánchez-Lozada LG, Andrews P, et al. Is there a pathogenic role for uric acid in fructose-induced metabolic syndrome? Endocr Rev 2013; 34(2): 266-86.
[http://dx.doi.org/10.1210/er.2012-1031]
[67]
Schwarz JM, Noworolski SM, Erkin-Cakmak A, et al. Effects of dietary fructose restriction on liver fat. Gastroenterology 2017; 153(3): 743-52.
[http://dx.doi.org/10.1053/j.gastro.2017.05.043] [PMID: 28579536]
[68]
Basu S, McKee M, Galea G, Stuckler D. Relationship of SSB taxes to obesity. PLoS Med 2013; 10(4) .
[http://dx.doi.org/10.1371/journal.pmed.1001576]
[69]
Guideline: Sugars Intake For Adults and Children. WHO 2015. Available from: https://www.who.int/publications/i/item/9789241 549028
[70]
Goran MI, Ulijaszek SJ, Ventura EE. High fructose corn syrup and diabetes prevalence: A global perspective. Glob Public Health 2013; 8(1): 55-64.
[http://dx.doi.org/10.1080/17441692.2012.736257] [PMID: 23181629]
[71]
Johnson RK, Appel LJ, Brands M, et al. Dietary sugars intake and cardiovascular health: A scientific statement from the American Heart Association. Circulation 2009; 120(11): 1011-20.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192627] [PMID: 19704096]
[72]
Popkin BM, Hawkes C. Sweetening of the global diet, particularly beverages: Patterns, trends, and policy responses. Lancet Diabetes Endocrinol 2016; 4(2): 174-86.
[http://dx.doi.org/10.1016/S2213-8587(15)00419-2] [PMID: 26654575]
[73]
Richelsen B. Sugar-sweetened beverages and obesity. Nutr Res Rev 2013; 26(2): 175-90.
[http://dx.doi.org/10.1017/S0954422413000128]
[74]
Drewnowski A, Rehm CD. Consumption of added sugars and nutrient intake. Am J Clin Nutr 2014; 99(3): 636-43.
[http://dx.doi.org/10.3945/ajcn.113.072165]
[75]
Ludwig DS, Peterson KE, Gortmaker SL. Sugar-sweetened beverages and weight gain. Lancet 2001; 357(9255): 505-8.
[http://dx.doi.org/10.1016/S0140-6736(00)04041-1] [PMID: 11229668]
[76]
Du M, Yan F, Yuan L, et al. Association between SSB taxes and BMI. Am J Public Health 2018; 108(11): 1419-26.
[http://dx.doi.org/10.2105/AJPH.2018.304595]
[77]
Suzanne VA, MHA MD, James ADL, et al. Sugar-sweetened beverages and metabolic syndrome. JAMA Netw Open 2020; 3(4) .
[http://dx.doi.org/10.1001/jamanetworkopen.2020.3032]
[78]
Sievenpiper JL, Chiavaroli L, de Souza RJ, et al. Fructose and cardiometabolic risks. Nutrients 2014; 6(7): 2602-18.
[http://dx.doi.org/10.3390/nu6072602] [PMID: 25025297]
[79]
Livesey G, Taylor R. Fructose and weight loss. Int J Obes 2008; 32(9): 1246-56.
[http://dx.doi.org/10.1038/ijo.2008.99]
[80]
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149(2): 367-378.e5.
[http://dx.doi.org/10.1053/j.gastro.2015.04.005] [PMID: 25865049]
[81]
Ismail I, Keating SE, Baker MK, Johnson NA. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat. Obes Rev 2012; 13(1): 68-91.
[http://dx.doi.org/10.1111/j.1467-789X.2011.00931.x] [PMID: 21951360]
[82]
Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2083-94.
[http://dx.doi.org/10.3748/wjg.v24.i19.2083] [PMID: 29785077]
[83]
Belančić A, Kenđel Jovanović G, Klobučar Majanović S. Obesity-related low-grade chronic inflammation: Implementation of the dietary inflammatory index in clinical practice is the milestone? Med Flum 2018; 54(4): 373-8.
[http://dx.doi.org/10.21860/medflum2018_207350]
[84]
Ryan MC, Itsiopoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol 2013; 59(1): 138-43.
[http://dx.doi.org/10.1016/j.jhep.2013.02.012] [PMID: 23485520]
[85]
Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2022. Diabetes Care 2022; 45 (Suppl. 1): S125-43.
[http://dx.doi.org/10.2337/dc22-S009] [PMID: 34964831]
[86]
Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2013; 1(1): 57-64.
[http://dx.doi.org/10.3892/br.2012.18] [PMID: 24648894]
[87]
Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87(6): 2784-91.
[http://dx.doi.org/10.1210/jcem.87.6.8567] [PMID: 12050251]
[88]
Bajaj M, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95(4): 1916-23.
[http://dx.doi.org/10.1210/jc.2009-0911] [PMID: 20157197]
[89]
Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis. JAMA Intern Med 2017; 177(5): 633-40.
[http://dx.doi.org/10.1001/jamainternmed.2016.9607] [PMID: 28241279]
[90]
Gimeno RE, Briere DA, Seeley RJ. Leveraging the gut to treat metabolic disease. Cell Metab 2020; 31(4): 679-98.
[http://dx.doi.org/10.1016/j.cmet.2020.02.014] [PMID: 32187525]
[91]
Cusi K, Bril F, Barb D, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab 2019; 21(4): 812-21.
[http://dx.doi.org/10.1111/dom.13584] [PMID: 30447037]
[92]
Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care 2019; 42(5): 931-7.
[http://dx.doi.org/10.2337/dc18-1569] [PMID: 30885955]
[93]
Kahl S, Gancheva S, Straßburger K, et al. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care 2020; 43(2): 298-305.
[http://dx.doi.org/10.2337/dc19-0641] [PMID: 31540903]
[94]
Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019; 21(2): 285-92.
[http://dx.doi.org/10.1111/dom.13520] [PMID: 30178600]
[95]
Pradhan R, Yin H, Yu O, Azoulay L. Glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes. Diabetes Care 2022; 45(4): 819-29.
[http://dx.doi.org/10.2337/dc21-1953] [PMID: 35104330]
[96]
Gastaldelli A, Repetto E, Guja C, et al. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab 2020; 22(3): 393-403.
[http://dx.doi.org/10.1111/dom.13907] [PMID: 31692226]
[97]
Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of medical care in diabetes Diabetes Care 2022; 45(1) .
[http://dx.doi.org/10.2337/dc22-S008]
[98]
Agarwal G, Patel M. Review on monoclonal antibodies (Mabs) as a therapeutic approach for type 1 diabetes. Curr Diabetes Rev 2024; 20(7): e310823220578.
[http://dx.doi.org/10.2174/1573399820666230831153249] [PMID: 37653635]
[99]
Caiazzo R, Lassailly G, Leteurtre E, et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: A 5-year controlled longitudinal study. Ann Surg 2014; 260(5): 893-9.
[http://dx.doi.org/10.1097/SLA.0000000000000945] [PMID: 25379859]
[100]
Shah R, Syn WK. Gut-liver axis and metabolic diseases: The role of bariatric surgery. Hepatology 2023; 78(4): 1701-10.
[http://dx.doi.org/10.1002/hep.32845]
[101]
Lee CJ, Brown TT. Weight loss and glycemic improvement after endoscopic and surgical interventions. Endocr Rev 2024; 45(1): 29-42.
[http://dx.doi.org/10.1210/endrev/bnac029]
[102]
Harbison S, Hackett B, Hart J, et al. Bariatric surgery outcomes in adolescents with severe obesity: A systematic review. Obes Surg 2024; 34(3): 915-25.
[http://dx.doi.org/10.1007/s11695-023-06634-7]
[103]
Courcoulas AP, Yanovski SZ, Wolfe BM. Current status of bariatric surgery. Ann Surg 2023; 278(2): 194-202.
[http://dx.doi.org/10.1097/SLA.0000000000005779]